Literature DB >> 8414018

The early course of the Tourette's syndrome clinical spectrum.

S Park1, P G Como, L Cui, R Kurlan.   

Abstract

We retrospectively studied 101 children with Tourette's syndrome to characterize the early course of illness and associated behavioral disturbances of attention deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), disruptive behavior (DB), and school problems (SP). For patients without ADHD (45%), OCD (50%), DB (67%), or SP (52%) at the time of initial evaluation, 13% developed ADHD, 8% OCD, 28% DB, and 25% SP during the observation period of 1.6 +/- 1.3 years (range, 0.5 to 7 years). For patients with behavioral disturbances initially, the problems were controlled or resolved for many over time and with therapy: ADHD, 46%; OCD, 47%; DB, 50%; and SP, 67%. Medication changes, assessed after a drug adjustment period between the initial and first follow-up visits (6 +/- 6 months), showed that drug dosages remained largely unchanged and few patients required the addition of new drugs: tic suppressants, 10%; anti-obsessional agents, 5%; and stimulants, 12%. Tic suppressants were withdrawn from 12%.

Entities:  

Mesh:

Year:  1993        PMID: 8414018     DOI: 10.1212/wnl.43.9.1712

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

1.  Neural substrates of self-regulatory control in children and adults with Tourette syndrome.

Authors:  Amir Raz; Hongtu Zhu; Shan Yu; Ravi Bansal; Zhishun Wang; Gerianne M Alexander; Jason Royal; Bradley S Peterson
Journal:  Can J Psychiatry       Date:  2009-09       Impact factor: 4.356

2.  A Brazilian cohort of patients with Tourette's syndrome.

Authors:  F Cardoso; C C Veado; J T de Oliveira
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-02       Impact factor: 10.154

Review 3.  Tourette's syndrome: are stimulants safe?

Authors:  Roger Kurlan
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.